121 related articles for article (PubMed ID: 20602317)
1. [Reversible posterior leukoencephalopathy syndrome associated to bevacizumab].
Ortiz-Lopez EM; Gonzalez-Nieto JA; Rojas-Marcos I; Blanco-Ollero A
Rev Neurol; 2010 Jul; 51(2):117-8. PubMed ID: 20602317
[No Abstract] [Full Text] [Related]
2. Reversible posterior leukoencephalopathy syndrome and intravenous bevacizumab.
Peter S; Hausmann N; Schuster A; Boehm HF
Clin Exp Ophthalmol; 2008; 36(1):94-6. PubMed ID: 18290962
[No Abstract] [Full Text] [Related]
3. Reversible posterior leukoencephalopathy syndrome caused by bevacizumab: report of a case.
Koopman M; Muller EW; Punt CJ
Dis Colon Rectum; 2008 Sep; 51(9):1425-6. PubMed ID: 18470563
[No Abstract] [Full Text] [Related]
4. Posterior reversible encephalopathy syndrome with bevacizumab.
Lau PC; Paunipagar B
Hong Kong Med J; 2011 Feb; 17(1):80-1. PubMed ID: 21282833
[No Abstract] [Full Text] [Related]
5. Reversible posterior leukoencephalopathy syndrome and bevacizumab in breast cancer.
Sclafani F; Giuseppe G; Mezynksi J; Collins C; Crown J
J Clin Oncol; 2012 Sep; 30(26):e257-9. PubMed ID: 22649141
[No Abstract] [Full Text] [Related]
6. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.
Allen JA; Adlakha A; Bergethon PR
Arch Neurol; 2006 Oct; 63(10):1475-8. PubMed ID: 17030665
[TBL] [Abstract][Full Text] [Related]
7. Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab.
Levy CF; Oo KZ; Fireman F; Pierre L; Bania MA; Sadanandan S; Yamashiro DJ; Glade Bender JL
Pediatr Blood Cancer; 2009 May; 52(5):669-71. PubMed ID: 19101996
[TBL] [Abstract][Full Text] [Related]
8. Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab.
El Maalouf G; Mitry E; Lacout A; Lièvre A; Rougier P
J Neurol; 2008 Feb; 255(2):295-6. PubMed ID: 18283405
[No Abstract] [Full Text] [Related]
9. Benign reversible encephalopathy syndrome after bevacizumab therapy for metastatic ovarian cancer.
Sawaya R; Radwan W; Hammoud S
Med Oncol; 2014 Feb; 31(2):831. PubMed ID: 24385223
[No Abstract] [Full Text] [Related]
10. Safety of bevacizumab in mild haemophilia B.
Lambert C; Deneys V; Pothen D; Hermans C
Thromb Haemost; 2008 May; 99(5):963-4. PubMed ID: 18449429
[No Abstract] [Full Text] [Related]
11. Hand eruption after intravenous administration of bevacizumab.
Ruiz V; Garcia-Muret MP; Alomar A
J Eur Acad Dermatol Venereol; 2011 Feb; 25(2):238-9. PubMed ID: 20477919
[No Abstract] [Full Text] [Related]
12. Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma.
Hosoi M; Yamamoto G; Imai Y; Kurokawa M
Ann Hematol; 2010 Feb; 89(2):207-8. PubMed ID: 19582454
[No Abstract] [Full Text] [Related]
13. Bevacizumab in lung cancer: hurdles in clinical development.
Pirker R
Lancet Oncol; 2010 Aug; 11(8):703-4. PubMed ID: 20650687
[No Abstract] [Full Text] [Related]
14. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Mrugala MM
Neurology; 2009 Feb; 72(8):773; author reply 773-4. PubMed ID: 19248218
[No Abstract] [Full Text] [Related]
15. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors.
Myint ZW; Sen JM; Watts NL; Druzgal TJ; Nathan BR; Ward MD; Boyer JE; Fracasso PM
Clin Colorectal Cancer; 2014 Jun; 13(2):127-30. PubMed ID: 24461491
[No Abstract] [Full Text] [Related]
16. Posterior reversible encephalopathy syndrome after bevacizumab therapy in a normotensive patient.
Abbas O; Shamseddin A; Temraz S; Haydar A
BMJ Case Rep; 2013 Feb; 2013():. PubMed ID: 23436889
[TBL] [Abstract][Full Text] [Related]
17. Diaphragmatic rupture, a new complication of Bevacizumab.
Lacaze L; Scotté M
Eur J Surg Oncol; 2012 Nov; 38(11):1079-81. PubMed ID: 22818843
[TBL] [Abstract][Full Text] [Related]
18. Nonconvulsive status epilepticus related to posterior reversible leukoencephalopathy syndrome induced by cetuximab.
Palma JA; Gomez-Ibañez A; Martin B; Urrestarazu E; Gil-Bazo I; Pastor MA
Neurologist; 2011 Sep; 17(5):273-5. PubMed ID: 21881470
[TBL] [Abstract][Full Text] [Related]
19. [Reversible posterior leukoencephalopathy: the guilty list is increasing].
Alaña M; Navarro M; Pascual J
Neurologia; 2008 Mar; 23(2):137; author reply 137-8. PubMed ID: 18322836
[No Abstract] [Full Text] [Related]
20. [Posterior Reversible Encephalopathy Syndrome (PRES): About 4 cases].
Chanal E; Bouleftour W; Rivoirard R; Bosaki C; Forges F; Jacquin JP; Fournel P; Mery B; Saban-Roche L
Presse Med; 2019 Oct; 48(10):1026-1031. PubMed ID: 31653541
[No Abstract] [Full Text] [Related]
[Next] [New Search]
